جميع الدراسات
التوظيفالمرحلة 3تدخلي

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

This study is testing a new medicine called etavopivat for people living with sickle cell disease. The main goal is to find out if etavopivat can reduce the number of painful events called vaso-occlusive crises (VOCs), which happen when blood vessels get blocked. We also want to see if this medicine can lessen damage to organs, help people exercise more easily, and reduce feelings of tiredness. Half of the participants will receive etavopivat, and the other half will receive a 'dummy pill' (placebo). Who gets which treatment is decided by chance. This study is expected to last for about two years and is part of the ongoing research into etavopivat.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 3
الراعي
Novo Nordisk A/S
الهدف من التسجيل
510
ابدأ
١٧ فبراير ٢٠٢٥
التاريخ المتوقع للانتهاء
12 Aug 2029

ما هو موضوع هذه الدراسة؟

This study is investigating a new medicine called etavopivat for people with sickle cell disease. Sickle cell disease is a lifelong condition that can cause severe pain and other serious health problems. These painful episodes are often called 'crises' or Vaso-occlusive crises (VOCs). They happen when the sickle-shaped red blood cells block small blood vessels, stopping blood from reaching parts of the body. This study wants to see if etavopivat can help reduce how often these painful crises occur.

Beyond reducing pain crises, the research team is also looking at other important aspects of living with sickle cell disease. They want to understand if etavopivat can help protect different organs in the body from the damage that can happen over time with this condition. They will also check if the medicine improves how well people can exercise and whether it reduces the common feeling of extreme tiredness, known as fatigue, that many people with sickle cell disease experience.

Overall, the aim is to confirm if etavopivat is a safe and effective treatment that could improve the lives of adults and teenagers with sickle cell disease. The study will compare etavopivat to a 'placebo', which is a dummy medicine with no active ingredients, to clearly see the effects of the new treatment.

النقاط الرئيسية

  • This study is testing a new medicine called etavopivat for sickle cell disease.
  • It aims to reduce painful crises, protect organs, and lessen tiredness.
  • Participants will receive either etavopivat or a dummy pill (placebo) by chance.
  • The study involves regular clinic visits and health checks over about two years.
  • If you have sickle cell and are aged 12 or older, you might be able to join.
  • يمكنك التوقف عن المشاركة في أي وقت دون التأثير على رعايتك الطبية.

من قد يكون مؤهلاً؟

To join this study, you need to be at least 12 years old, male or female, and have been diagnosed with sickle cell disease. This diagnosis needs to be confirmed by past medical tests like a blood test (haemoglobin electrophoresis or HPLC). You must also have experienced between 1 and 15 painful sickle cell crises (VOCs) in the 12 months before the study starts. These crises need to be recorded in your medical notes, not just remembered.

Your blood test results at the start of the study (called 'screening') also need to show that your haemoglobin levels are somewhere between 5.0 and 10.0 grams per decilitre. This helps ensure that the medicine is being tested in people who fit certain medical criteria for the study.

There are also some reasons why you couldn't take part. For example, if you've had more than 15 painful crises in the last year, or if you're currently having regular blood transfusions. Also, if you use certain other medicines for sickle cell disease, like voxelotor or crizanlizumab, you might not be able to join, or you might need to stop them a certain amount of time before starting the study.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. هل عمرك 12 سنة أو أكثر؟
  2. Do you have a confirmed diagnosis of sickle cell disease?
  3. Have you had between 1 and 15 painful sickle cell crises (VOCs) in the last year, documented by a doctor?
  4. Are you NOT currently receiving regular, planned blood transfusions?
  5. Are you NOT currently taking certain other specific sickle cell medicines?
  6. Is your haemoglobin level, as measured by a doctor, between 5.0 and 10.0 g/dL?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part in this study, you'll either receive the new medicine, etavopivat, or a dummy pill (placebo). Which one you get will be decided by chance, like flipping a coin. You won't know which one you're receiving, and neither will your study doctor. This is to make sure the results are fair.

Throughout the study, you'll have regular visits to the clinic where the study team will monitor your health, ask about your symptoms (like pain crises and tiredness), and perform tests. These tests might include blood samples and checks on how well your organs are working. They'll also check your exercise ability. The total study duration is expected to be about two years, involving ongoing treatment and follow-up during this time.

المخاطر والفوائد المحتملة

Taking part in any medical study has potential benefits and risks. A potential benefit of joining this study is that you might receive access to a new medicine, etavopivat, which could potentially reduce your painful crises, organ damage, and tiredness, and improve your ability to exercise. However, there's also a chance you might receive the placebo, which means you wouldn't directly benefit from the experimental medicine. There could be side effects from taking etavopivat, and these will be carefully explained to you by the study team. They will monitor your health very closely throughout the study. It's important to remember that you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (175)

  • Uni of Alabama at Birmingham
    الرمز البريدي المؤكد
    برمنغهام، الولايات المتحدة· التوظيف
  • Univer South Alabama Ped/Onc
    الرمز البريدي المؤكد
    Mobile, United States· التوظيف
  • Phoenix Children's Hsptl
    الرمز البريدي المؤكد
    فينيكس، الولايات المتحدة· التوظيف
  • Arkansas Children's Hospital
    الرمز البريدي المؤكد
    ليتل روك، الولايات المتحدة· التوظيف
  • Children's Hospital Los Angeles - Endocrinology
    الرمز البريدي المؤكد
    لوس أنجلوس، الولايات المتحدة· التوظيف
  • UCLA Health
    الرمز البريدي المؤكد
    لوس أنجلوس، الولايات المتحدة· مكتمل
  • Valley Children's Hospital
    الرمز البريدي المؤكد
    ماديرا، الولايات المتحدة· التوظيف
  • University Of California Irvine
    الرمز البريدي المؤكد
    أورانج، الولايات المتحدة· مكتمل
  • Stanford University_Palo Alto
    الرمز البريدي المؤكد
    بالو ألتو، الولايات المتحدة· التوظيف
  • Harbor-UCLA Medical Center
    الرمز البريدي المؤكد
    تورانس، الولايات المتحدة· التوظيف
  • Clinical and Transl Res Center
    الرمز البريدي المؤكد
    أورورا، الولايات المتحدة· مكتمل
  • Nemours/AI duPont Hosp-Chld
    الرمز البريدي المؤكد
    ويلمنجتون، الولايات المتحدة· التوظيف

أسئلة شائعة

What is etavopivat?

Etavopivat is a new medicine being tested to see if it helps people with sickle cell disease by possibly reducing painful crises and improving other symptoms.

ما هو "العلاج الوهمي"؟

A placebo is a 'dummy' pill that looks like the study medicine but doesn't contain any active ingredients. It's used to compare the real medicine's effects.

كم ستستغرق مدة الدراسة؟

The study is expected to last for about two years for each participant.

هل سأعرف إذا كنت أحصل على الدواء الحقيقي أم الدواء الوهمي؟

No, neither you nor your study doctor will know whether you are receiving etavopivat or the placebo. This helps ensure fair and accurate study results.

Will taking part in this study change my regular medical care?

Participating in the study shouldn't stop you from receiving your usual care, but some treatments might need to be paused or adjusted during the study. This will be discussed in detail.

كيفية معرفة المزيد

Novo Nordisk

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "A Study to Evaluate How Well Etavopivat Works in People With… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.